vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $180.9M, roughly 2.0× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -0.8%, a 0.1% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 0.7%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ASIX vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $180.9M |
| Net Profit | $-2.8M | $-1.3M |
| Gross Margin | 7.6% | 47.5% |
| Operating Margin | -0.7% | 1.4% |
| Net Margin | -0.8% | -0.7% |
| Revenue YoY | 9.4% | 0.7% |
| Net Profit YoY | -892.9% | 99.7% |
| EPS (diluted) | $-0.11 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $180.9M | ||
| Q3 25 | $374.5M | $177.8M | ||
| Q2 25 | $410.0M | $175.0M | ||
| Q1 25 | $377.8M | $167.5M | ||
| Q4 24 | $329.1M | $179.6M | ||
| Q3 24 | $398.2M | $170.4M | ||
| Q2 24 | $453.5M | $171.7M | ||
| Q1 24 | $336.8M | $166.1M |
| Q4 25 | $-2.8M | $-1.3M | ||
| Q3 25 | $-2.6M | $-1.4M | ||
| Q2 25 | $31.4M | $-76.8M | ||
| Q1 25 | $23.3M | $6.6M | ||
| Q4 24 | $352.0K | $-397.3M | ||
| Q3 24 | $22.3M | $4.3M | ||
| Q2 24 | $38.9M | $1.8M | ||
| Q1 24 | $-17.4M | $-900.0K |
| Q4 25 | 7.6% | 47.5% | ||
| Q3 25 | 6.8% | 48.4% | ||
| Q2 25 | 14.3% | 52.6% | ||
| Q1 25 | 14.2% | 53.6% | ||
| Q4 24 | 3.4% | 54.6% | ||
| Q3 24 | 14.4% | 54.5% | ||
| Q2 24 | 17.9% | 55.7% | ||
| Q1 24 | 0.9% | 57.1% |
| Q4 25 | -0.7% | 1.4% | ||
| Q3 25 | -0.9% | 0.1% | ||
| Q2 25 | 7.7% | -42.6% | ||
| Q1 25 | 7.7% | 6.1% | ||
| Q4 24 | -3.9% | -233.0% | ||
| Q3 24 | 7.5% | 7.0% | ||
| Q2 24 | 11.5% | 3.7% | ||
| Q1 24 | -7.0% | 2.4% |
| Q4 25 | -0.8% | -0.7% | ||
| Q3 25 | -0.7% | -0.8% | ||
| Q2 25 | 7.7% | -43.9% | ||
| Q1 25 | 6.2% | 3.9% | ||
| Q4 24 | 0.1% | -221.2% | ||
| Q3 24 | 5.6% | 2.5% | ||
| Q2 24 | 8.6% | 1.0% | ||
| Q1 24 | -5.2% | -0.5% |
| Q4 25 | $-0.11 | $-0.02 | ||
| Q3 25 | $-0.10 | $-0.03 | ||
| Q2 25 | $1.15 | $-1.66 | ||
| Q1 25 | $0.86 | $0.14 | ||
| Q4 24 | $0.02 | $-8.64 | ||
| Q3 24 | $0.82 | $0.09 | ||
| Q2 24 | $1.43 | $0.04 | ||
| Q1 24 | $-0.65 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $89.8M |
| Total DebtLower is stronger | — | $90.3M |
| Stockholders' EquityBook value | $815.2M | $778.2M |
| Total Assets | $1.7B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $89.8M | ||
| Q3 25 | $23.7M | $70.5M | ||
| Q2 25 | $18.4M | $90.3M | ||
| Q1 25 | $8.3M | $97.0M | ||
| Q4 24 | $19.6M | $107.7M | ||
| Q3 24 | $17.3M | $89.0M | ||
| Q2 24 | $12.1M | $92.2M | ||
| Q1 24 | $20.6M | $75.8M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $815.2M | $778.2M | ||
| Q3 25 | $818.2M | $778.0M | ||
| Q2 25 | $823.7M | $776.3M | ||
| Q1 25 | $794.4M | $839.4M | ||
| Q4 24 | $774.6M | $828.5M | ||
| Q3 24 | $766.4M | $1.2B | ||
| Q2 24 | $746.6M | $1.2B | ||
| Q1 24 | $713.2M | $1.2B |
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.5B | $1.7B |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $28.2M |
| Free Cash FlowOCF − Capex | $36.1M | $21.3M |
| FCF MarginFCF / Revenue | 10.0% | 11.8% |
| Capex IntensityCapex / Revenue | 7.7% | 3.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $28.2M | ||
| Q3 25 | $26.6M | $14.0M | ||
| Q2 25 | $21.1M | $6.8M | ||
| Q1 25 | $11.4M | $25.7M | ||
| Q4 24 | $64.2M | $57.9M | ||
| Q3 24 | $57.3M | $23.0M | ||
| Q2 24 | $50.2M | $27.8M | ||
| Q1 24 | $-36.2M | $-8.0M |
| Q4 25 | $36.1M | $21.3M | ||
| Q3 25 | $66.0K | $7.0M | ||
| Q2 25 | $-7.2M | $-4.2M | ||
| Q1 25 | $-22.6M | $19.0M | ||
| Q4 24 | $29.8M | $53.1M | ||
| Q3 24 | $26.8M | $20.0M | ||
| Q2 24 | $16.7M | $21.9M | ||
| Q1 24 | $-71.6M | $-12.1M |
| Q4 25 | 10.0% | 11.8% | ||
| Q3 25 | 0.0% | 3.9% | ||
| Q2 25 | -1.7% | -2.4% | ||
| Q1 25 | -6.0% | 11.3% | ||
| Q4 24 | 9.1% | 29.6% | ||
| Q3 24 | 6.7% | 11.7% | ||
| Q2 24 | 3.7% | 12.8% | ||
| Q1 24 | -21.3% | -7.3% |
| Q4 25 | 7.7% | 3.8% | ||
| Q3 25 | 7.1% | 3.9% | ||
| Q2 25 | 6.9% | 6.3% | ||
| Q1 25 | 9.0% | 4.0% | ||
| Q4 24 | 10.4% | 2.7% | ||
| Q3 24 | 7.7% | 1.8% | ||
| Q2 24 | 7.4% | 3.4% | ||
| Q1 24 | 10.5% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | 3.89× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | 5.35× | ||
| Q2 24 | 1.29× | 15.44× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
